STOCKHOLM, July 1, 2014 - Karo Bio AB (publ) has been awarded another SEK 3.8 million from Vinnova for the preclinical development of an ERbeta agonist for the treatment of different forms of cancer. In total, Karo Bio has thus been granted SEK 4.8 million for the project from Vinnova. The financing is granted through the Forska & Väx program and will be paid out in stages during 2014 and early 2015, to finance studies within Karo Bio’s project ERbeta cancer, including initiated toxicity and safety pharmacology studies. Previously in 2014, Vinnova granted Karo Bio about SEK 1 million for these studies.
Help employers find you! Check out all the jobs and post your resume.
